Physician profile
Megan E Windom
NPI 1700521804
$2,979.78
in general payments reported to CMS, 2019-2025
21 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $262 · 2023: $1,085 · 2024: $1,421 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $663.65 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $414.13 | 2022-2024 | Gattex, Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.00 | 2022-2024 | Xifaxan, Trulance |
| Genzyme Corporation | $254.84 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $251.54 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $235.37 | 2022-2024 | Dificid |
| Madrigal Pharmaceuticals | $202.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $96.00 | 2023 | |
| Ardelyx, INC. | $82.98 | 2023-2024 | Ibsrela |
| Qol Medical, LLC | $76.10 | 2022 | |
| Ironwood Pharmaceuticals, INC | $67.94 | 2023-2024 | Linzess |
| Pfizer INC. | $58.51 | 2024 | |
| Braintree Laboratories, INC. | $54.08 | 2024 | Suflave |
| Lilly USA, LLC | $50.17 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $44.86 | 2024 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $42.92 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $34.05 | 2023 | Givlaari |
| Blueprint Medicines Corporation | $27.06 | 2025 | Ayvakit |
| Aimmune Therapeutics, INC. | $21.18 | 2024 | |
| Medtronic, INC. | $16.67 | 2023 | Interstim |
| Intercept Pharmaceuticals, INC. | $15.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Windom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.